Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis

Published:2018-10 Issue:10 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Illamola Sílvia M.¹,Huynh Hoa Q.²,Liu Xiaoxi¹,Bhakta Zubin N.³,Sherwin Catherine M.¹²,Liou Theodore G.³⁴⁵^ORCID,Carveth Holly³⁴,Young David C.²³

Affiliation:

1. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA

2. University of Utah College of Pharmacy, Salt Lake City, Utah, USA

3. The Adult Cystic Fibrosis Center, University of Utah, Salt Lake City, Utah, USA

4. Division of Respiratory, Critical Care and Occupational Pulmonary Medicine, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA

5. The Center for Quantitative Biology, University of Utah, Salt Lake City, Utah, USA

Abstract

Practitioners commonly use amikacin in patients with cystic fibrosis. Establishment of the pharmacokinetics of amikacin in adults with cystic fibrosis may increase the efficacy and safety of therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00877-18

Reference43 articles.

1. Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy

2. Cystic fibrosis

3. Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases;Oppenheimer EH;Perspect Pediatr Pathol,1975

4. Pulmonary complications of cystic fibrosis;Flume PA;Respir Care,2009

5. Management of Pulmonary Disease in Patients with Cystic Fibrosis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biased computation of probability of target attainment for antimicrobial drugs;CPT: Pharmacometrics & Systems Pharmacology;2023-04-06

2. Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis;European Journal of Drug Metabolism and Pharmacokinetics;2021-12-09

3. Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis;Antimicrobial Agents and Chemotherapy;2021-09-17

4. A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis;Therapeutic Drug Monitoring;2021-08

5. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis;Clinical Pharmacokinetics;2021-05-13